No modulatory effect of neurokinin-1 receptor antagonists on serotonin uptake in human and rat brain synaptosomes.
Some studies have demonstrated antidepressant activity of neurokinin-1-receptor antagonists (NK-1-RA) in major depressive disorder. However, the underlying mechanisms of this antidepressant effect are largely unknown. Preclinical studies in rats and mice have suggested that NK-1-RA do increase the neuronal release of serotonin (5-HT). This, however, seems to be compensated by an increased 5-HT reuptake, indicating that NK-1-RA have no inhibitory effect on the 5-HT transporter in rodents. Given the possibility that modulation of neurotransmitter release and reuptake may differ between species, with major differences found between rodents and humans, we investigated for the first time the possible modulatory effect of NK-1-RA on 5-HT uptake in human brain synaptosomes and compared it with the situation in rat cortex. We found that the specific human NK-1-RA L-733060, in contrast to the SSRI fluvoxamine (IC50=10(-7.96)M) did not inhibit 5-HT uptake in human brain synaptosomes and did not modulate fluvoxamine-induced 5-HT uptake inhibition at 1 muM. Furthermore, substance P as well as Sar9Met(O2)11SP, as the major agonists at the NK-1-R, did not modulate 5-HT uptake in human brain synaptosomes. Similar results were found in rat cortex synaptosomes by using the rat-specific NK-1-RA WIN51708. These results show that in humans, as in rodents, inhibition of the 5-HT transporter is probably not the underlying mechanism of the assumed antidepressant activity of NK-1-RA.
Department of Psychiatry and Psychotherapy, University of Freiburg Medical School, Hauptstr. 5, D-79104 Freiburg, Germany. klaus_lieb@psyallg.ukl.uni-freiburg.de
Klaus
K
Lieb
Bernd L
BL
Fiebich
Inga
I
Herpfer
Michela
M
Mantovani
Marlene
M
Löffler
Thomas J
TJ
Feuerstein
D000293:Adolescent; D000328:Adult; D000368:Aged; D000731:Androstanes / Q000494:pharmacology; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D015153:Blotting, Western; D001923:Brain Chemistry / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D016666:Fluvoxamine / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D019579:Neocortex / Q000187:drug effects / Q000378:metabolism; D064729:Neurokinin-1 Receptor Antagonists; D051381:Rats; D017208:Rats, Wistar; D012701:Serotonin / Q000378:metabolism*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D013373:Substance P / Q000378:metabolism; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism*
D000731:Androstanes; D001562:Benzimidazoles; D016666:Fluvoxamine; D064729:Neurokinin-1 Receptor Antagonists; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D013373:Substance P; C086111:WIN 51708